Congress Materials – Florida Society of Rheumatology (FSR 2025)
2025 Florida Society of Rheumatology | Jun 19-22 | Lake Buena Vista, Florida
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Efficacy and Safety of Subcutaneous Guselkumab Induction Therapy in Patients with Ulcerative Colitis: Results Through Week 12 from the Phase 3 ASTRO Study
Laurent Peyrin-Biroulet, Jessica R. Allegretti, Silvio Danese, Matthew Germinaro, Thomas Baker, Yelina Alvarez, Silke Jörgens, Lingjing Jiang, Hongyan Zhang, Alejandro Lizano Corzo, Tadakazu Hisamatsu, David T. Rubin, Millie Long
This document will be available on June 19 2025
Inhibition of Structural Damage Progression with Guselkumab in Participants with Active PsA: Results Through Week 24 of the Phase 3b, Randomized, Double-Blind APEX Study
Philip J. Mease, Christopher T. Ritchlin, Laura C. Coates, Alexa P. Kollmeier, Bei Zhou, Yusang Jiang, Karen Bensley, Koeun Im, Rattandeep Batra, Stacey Fitch, Soumya D. Chakravarty, Proton Rahman, Désirée van der Heijde
This document will be available on June 19 2025
Real-World On-Label Treatment Persistence Through 24 Months in Biologic-Naïve & Biologic-Experienced Patients With PsA: Comparison of Guselkumab vs Subcutaneous IL-17Ai
Philip J. Mease, Jessica Walsh, Timothy P. Fitzgerald, Soumya D. Chakravarty, Elizabeth Adamson, Anthony Todd, Bruno Emond, Carmine Rossi, Samuel Schwartzbein, Kana Yokoji, Yuxi Wang, Patrick Lefebvre, Dominic Pilon, Shikha Singla, Joseph F. Merola
This document will be available on June 19 2025
Real-World On-Label Treatment Persistence Through 24 Months in Biologic-Naïve & Biologic-Experienced Patients With Psoriatic Arthritis: Guselkumab vs Subcutaneous TNFi
Philip J. Mease, Jessica Walsh, Timothy P. Fitzgerald, Soumya D. Chakravarty, Elizabeth Adamson, Anthony Todd, Bruno Emond, Carmine Rossi, Samuel Schwartzbein, Kana Yokoji, Yuxi Wang, Patrick Lefebvre, Dominic Pilon, Shikha Singla, Joseph F. Merola
This document will be available on June 19 2025
Safety of Guselkumab in Inflammatory Bowel Disease Up to 1 Year: Integrated Safety Analysis of Phase 2 and 3 Studies in Crohn’s Disease and Ulcerative Colitis
Bruce E. Sands, Remo Panaccione, Silvio Danese, Julián Panés, Tadakazu Hisamatsu, Geert D’Haens, Rian Van Rampelbergh, Mobolaji Olurinde, Jacqueline Yee, Thomas Baker, Shadi Yarandi, Matthew Germinaro, Marion L. Vetter, Hewei Li, Kate Callaway, Mauricio Rosas Ballina, Jessica R. Allegretti, Anita Afzali, David T. Rubin
This document will be available on June 19 2025
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.